Optimizing Rheumatology Prior Authorization with Inovalon Clearinghouse

Klivira provides a robust solution for rheumatology practices to automate prior authorizations, seamlessly integrating with the Inovalon Clearinghouse for efficient submission and status management.

Revenue cycle directors and prior authorization coordinators in rheumatology face a high burden of complex PAs, particularly for high-cost biologics and targeted therapies. The need for precise documentation, adherence to step therapy protocols, and efficient clearinghouse interaction is paramount. Klivira addresses these challenges by streamlining the PA workflow from EMR to payer, leveraging Inovalon's clearinghouse capabilities.

The Rheumatology PA Burden: Biologics and Advanced Therapies

Rheumatology prior authorizations are heavily concentrated in biologic and targeted synthetic DMARDs such as TNF-alpha inhibitors (e.g., adalimumab, etanercept, infliximab) and non-TNF biologics (e.g., IL-6, IL-17, IL-23 inhibitors, JAK inhibitors). These high-cost medications for chronic conditions like RA, PsA, and AS necessitate frequent, detailed PAs. Klivira's platform is engineered to manage the specific complexities of these authorizations, ensuring all required clinical data is captured before submission via Inovalon.

Critical Documentation for Rheumatology PA Success

**Diagnosis Documentation:** ICD-10 codes paired with disease-specific criteria (e.g., 2010 ACR/EULAR for RA, CASPAR for PsA, modified New York or ASAS for AS, 2019 EULAR/ACR for SLE).
**Disease Activity Assessment:** Standardized scores like DAS28, CDAI, SDAI for RA; PASI/BSA for psoriasis; BASDAI for AS; SLEDAI for SLE.
**Prior Conventional DMARD Trial:** Documentation of methotrexate, sulfasalazine, or other csDMARD trial and response, or contraindication.
**Step Therapy Compliance:** Evidence of failure for specific prior agents, including biosimilar substitution requirements before brand approval.
**Screening Completion:** Mandatory TB, hepatitis B/C screening, and immunization status prior to initiating immunosuppressive biologics.

Integrating Klivira with Inovalon for Rheumatology Workflows

Inovalon Clearinghouse serves as a critical conduit for electronic healthcare transactions, including prior authorizations. Klivira integrates with your EMR to extract relevant clinical data, apply ACR-guideline-aware policy logic, and then format the PA request for seamless submission through Inovalon using standard X12 278 transactions. This integration ensures that rheumatology practices can efficiently route complex medical and pharmacy benefit PAs, including those for self-administered vs. provider-administered biologics, minimizing manual intervention and accelerating approval times.

Mitigating Common Rheumatology PA Denials

Common denial reasons in rheumatology, such as incomplete step therapy documentation, failure to attempt biosimilar substitution, or missing disease activity scores, significantly impact revenue. Klivira's automated workflows proactively identify and flag these gaps before submission. Our system's policy logic, informed by payer-specific rules and ACR treatment guidelines, helps ensure that all necessary criteria are met, reducing the likelihood of denials and the need for costly appeals for agents like JAK inhibitors or specific specialty drugs.

Continuous Authorization and Pediatric Considerations

The chronic nature of rheumatologic conditions means ongoing prior authorization burden for maintenance therapies. Klivira supports periodic re-authorization workflows, prompting for continuous disease response documentation. For pediatric rheumatology, our system incorporates pediatric-specific dosing, weight-based PA, and guideline criteria, adding an essential layer of specificity for this sensitive patient population.

Frequently asked questions

How does Klivira handle the medical vs. pharmacy benefit split for rheumatology biologics?

Klivira's platform intelligently routes prior authorization requests for biologics based on their administration mode (self-administered vs. provider-administered) and the specific payer's policy. This ensures the correct benefit channel is addressed, whether it falls under medical or pharmacy benefits, streamlining the process for agents like TNF inhibitors.

What role does Inovalon Clearinghouse play in Klivira's rheumatology PA workflow?

Inovalon Clearinghouse acts as the secure electronic pathway for transmitting prior authorization requests from Klivira to various payers. Klivira prepares the comprehensive PA package, including all necessary clinical documentation, and then leverages Inovalon for efficient, compliant submission and status updates via X12 278 transactions, ensuring rapid communication between provider and payer.

Does Klivira's system incorporate ACR Treatment Guidelines for rheumatology PAs?

Yes, Klivira's policy logic is designed with an awareness of the ACR Treatment Guidelines, which are the dominant framework for indication-specific treatment escalation in rheumatology. This ensures that our automated workflows align with clinical best practices for conditions like RA, PsA, and AS, guiding users through appropriate step therapy sequencing and documentation requirements.

How does Klivira address biosimilar substitution mandates in rheumatology?

Klivira's platform includes specific routing and policy logic to manage per-payer biosimilar mandates. For rheumatology, where biosimilar substitution is common for TNF-alpha inhibitors, our system helps ensure compliance with payer requirements, guiding staff on when and how to document biosimilar trials or substitutions to avoid denials.

Can Klivira integrate with our existing EMR for rheumatology PA data?

Yes, Klivira specializes in robust EMR integrations, including SMART on FHIR capabilities, to seamlessly extract patient demographics, diagnoses, medication lists, and clinical notes relevant for rheumatology prior authorizations. This reduces manual data entry and ensures that the PA request submitted through Inovalon is complete and accurate.